JP2023524990A - ＳＡＲＳ－ＣｏＶ－２スパイクタンパク質を発現する組換えニューカッスル病ウイルス及びその使用 - Google Patents

ＳＡＲＳ－ＣｏＶ－２スパイクタンパク質を発現する組換えニューカッスル病ウイルス及びその使用 Download PDF

Info

Publication number
JP2023524990A
JP2023524990A JP2022567321A JP2022567321A JP2023524990A JP 2023524990 A JP2023524990 A JP 2023524990A JP 2022567321 A JP2022567321 A JP 2022567321A JP 2022567321 A JP2022567321 A JP 2022567321A JP 2023524990 A JP2023524990 A JP 2023524990A
Authority
JP
Japan
Prior art keywords
ndv
protein
cov
sars
transgene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022567321A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524990A5 (https=
JPWO2021226348A5 (https=
Inventor
サン ウェイナ
クラムメル フロリアン
ガルシア‐サストレ アドルフォ
パレセ ピーター
Original Assignee
アイカーン スクール オブ メディシン アット マウント サイナイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2021/022848 external-priority patent/WO2021194826A2/en
Application filed by アイカーン スクール オブ メディシン アット マウント サイナイ filed Critical アイカーン スクール オブ メディシン アット マウント サイナイ
Publication of JP2023524990A publication Critical patent/JP2023524990A/ja
Publication of JP2023524990A5 publication Critical patent/JP2023524990A5/ja
Publication of JPWO2021226348A5 publication Critical patent/JPWO2021226348A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022567321A 2020-05-07 2021-05-06 ＳＡＲＳ－ＣｏＶ－２スパイクタンパク質を発現する組換えニューカッスル病ウイルス及びその使用 Pending JP2023524990A (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US202063021677P 2020-05-07 2020-05-07
US63/021,677 2020-05-07
US202063051858P 2020-07-14 2020-07-14
US63/051,858 2020-07-14
US202063057267P 2020-07-27 2020-07-27
US63/057,267 2020-07-27
US202063058435P 2020-07-29 2020-07-29
US63/058,435 2020-07-29
US202063059924P 2020-07-31 2020-07-31
US63/059,924 2020-07-31
PCT/US2021/022848 WO2021194826A2 (en) 2020-03-24 2021-03-17 Recombinant sars-cov-2 spike protein and uses thereof
USPCT/US2021/022848 2021-03-17
PCT/US2021/031110 WO2021226348A2 (en) 2020-05-07 2021-05-06 Recombinant newcastle disease virus expressing sars-cov-2 spike protein and uses thereof

Publications (3)

Publication Number Publication Date
JP2023524990A true JP2023524990A (ja) 2023-06-14
JP2023524990A5 JP2023524990A5 (https=) 2024-05-29
JPWO2021226348A5 JPWO2021226348A5 (https=) 2024-05-29

Family

ID=78468787

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022567321A Pending JP2023524990A (ja) 2020-05-07 2021-05-06 ＳＡＲＳ－ＣｏＶ－２スパイクタンパク質を発現する組換えニューカッスル病ウイルス及びその使用

Country Status (7)

Country Link
US (1) US20230310583A1 (https=)
EP (1) EP4146674A4 (https=)
JP (1) JP2023524990A (https=)
BR (1) BR112022022604A2 (https=)
CA (1) CA3178875A1 (https=)
MX (1) MX2022013934A (https=)
WO (1) WO2021226348A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021229270A1 (es) * 2020-05-13 2021-11-18 Laboratorio Avi-Mex, S.A. De C.V. Vacuna recombinante contra covid-19 en vector viral
CN113881704B (zh) * 2021-11-17 2024-02-13 浙江迪福润丝生物科技有限公司 一种包含新型冠状病毒双抗原靶标序列组合的重组新城疫病毒载体及相应疫苗株和疫苗
CN114196701B (zh) * 2021-11-17 2023-10-10 浙江迪福润丝生物科技有限公司 一种sars-cov-2的二价重组新城疫病毒载体及相应疫苗株和制备方法
CN117247463A (zh) * 2021-12-16 2023-12-19 浙江迪福润丝生物科技有限公司 一种展示新冠病毒s蛋白的融合蛋白和重组病毒粒子及其应用
KR20240137110A (ko) * 2022-02-02 2024-09-19 워싱턴 유니버시티 오미크론 코로나바이러스 백신 구조체 및 이를 제조하고 사용하는 방법
JP2025509352A (ja) * 2022-03-10 2025-04-11 アイカーン スクール オブ メディスン アット マウント サイナイ Ｃｏｖｉｄ－１９の予防に使用するための組み換え型ニューカッスル病ウイルスおよび免疫原性組成物
US20250228929A1 (en) * 2022-04-03 2025-07-17 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and immunogenic compositions for use in immunizing against sars-cov-2 omicron variant
WO2024174012A1 (pt) * 2023-02-24 2024-08-29 Instituto Butantan Composição imunogênica, uso da mesma e processo de obtenção de uma composição imunogênica combinada contra covid-19 e influenza sazonal

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009518007A (ja) * 2005-12-02 2009-05-07 トヘ モウント シナイ スクール オフ メディシネ オフ ニューヨーク ウニベルシトイ 非天然表面タンパク質を提示するキメラウイルス及びその使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019011599A (es) * 2017-03-30 2019-12-19 Univ Queensland Moleculas quimericas y usos de las mismas.
US20190382450A1 (en) * 2018-06-18 2019-12-19 University Of Maryland, College Park Newcastle disease virus-based vectored vaccine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009518007A (ja) * 2005-12-02 2009-05-07 トヘ モウント シナイ スクール オフ メディシネ オフ ニューヨーク ウニベルシトイ 非天然表面タンパク質を提示するキメラウイルス及びその使用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Accession No. MN908947", DATABASE GENBANK, JPN6025017049, 18 March 2020 (2020-03-18), ISSN: 0005748824 *
"Accession No. MT380725", DATABASE GENBANK, JPN6025017050, 27 April 2020 (2020-04-27), ISSN: 0005748823 *
HSIEH, C. ET AL.: "Structure-based Design of Prefusion-stabilized SARS-CoV-2 Spikes", BIORXIV, JPN6025017047, 30 May 2020 (2020-05-30), pages 1 - 24, ISSN: 0005748825 *
PNAS, vol. 104, JPN6025017046, 2007, pages 23, ISSN: 0005748822 *

Also Published As

Publication number Publication date
MX2022013934A (es) 2023-02-22
BR112022022604A2 (pt) 2023-03-28
WO2021226348A3 (en) 2021-12-09
CA3178875A1 (en) 2021-11-11
EP4146674A2 (en) 2023-03-15
EP4146674A4 (en) 2024-07-10
US20230310583A1 (en) 2023-10-05
WO2021226348A2 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
US9849172B2 (en) Influenza virus vaccines and uses thereof
JP2023524990A (ja) ＳＡＲＳ－ＣｏＶ－２スパイクタンパク質を発現する組換えニューカッスル病ウイルス及びその使用
JP2022091775A (ja) インフルエンザウイルスワクチン及びその使用
US9701723B2 (en) Vaccines for use in the prophylaxis and treatment of influenza virus disease
US10752916B2 (en) Parainfluenza virus 5 based vaccines
US20250041402A1 (en) Recombinant newcastle disease virus expressing spike protein of sars-cov-2 delta variant and uses thereof
US20250228929A1 (en) Recombinant newcastle disease viruses and immunogenic compositions for use in immunizing against sars-cov-2 omicron variant
US20240199705A1 (en) Chimeric newcastle disease virus expressing apmv hn and f proteins
JP6616096B2 (ja) 組換え麻疹ウイルス
US20250186578A1 (en) Recombinant newcastle disease viruses and immunogenic compositions for use in preventing covid-19
US20250250304A1 (en) Recombinant newcastle disease virus expressing lassa virus gp or np, and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240521

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250423

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250430

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250728

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20250822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251027

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260304